Andy Studna, Senior Editor

Recent study proposes consensus-based extension to the Consolidated Standards of Reporting Trials 2010 Statement for factorial trials.

Aligning best practices in eCOA and ePRO within today’s evolving technology ecosystem.

How the Medical Information Data Uses For AI Semantic Analysis tool is saving pharma valuable time and resources in identifying data points.

Research shows GenAI has greater potential for a more immediate impact than previous digital technologies implemented in healthcare.

Jared Baeten, Vice President, Clinical Development, HIV Franchise Head at Gilead Sciences highlights how awareness and clinical innovation have transformed research in the HIV space.

Despite regulatory guidance, disability status is frequently unreported or overlooked in trial design.

Results from decade-long analysis suggest great improvement is needed in the quality of control groups.

Increased use of laboratory-developed tests emphasizes inaccuracy and need for regulatory intervention.

Increased use of fentanyl underscores immediate need for better testing methods.

New research initiative will investigate the potential of zanidatamab as a monotherapy and in combination with other treatments for patients with different tumor types and stages.

Ongoing phase 1 dose-escalation trial of KO-2806 (FIT-001) for the treatment of patients with KRASG12C-mutated non-small cell lung cancer expected to begin dosing patients in combination with adagrasib by mid-2024.

New laws leave consumers unprotected against third parties accessing their genetic data.

Exagamglogene autotemcel (exa-cel) has shown the potential to be a landmark therapy in preventing episodes of excruciating pain among patients with sickle cell disease.

Insightful sound bytes from KOLs attending SCOPE EUROPE 2023.

Interactive panel discussed the evolving area of data transfer and the usage of EHR-to-EDC.

Industry leaders gathered to address the current landscape of data collection in clinical trials.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies addresses what stakeholders should be thinking of in the data collection space moving forward.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how regulatory bodies are currently viewing the data collection space.

In an interview at SCOPE Europe 2023 with Applied Clinical Trials Editor, Andy Studna, Tony Mikulaschek, VP, eCOA, IQVIA Technologies discusses how eCOAs are being applied to clinical trials.

With so many new solutions and other technologies appearing in the clinical trials space, how are stakeholders choosing which ones are best for them and how are these advancements translating to the actual clinic?

While clinical research in rare diseases has many unique operational challenges, there is plenty of work being done to advance it and bring effective therapies to patients.

Bingham discusses the logistical challenges associated with coordinating patient involvement in rare disease clinical trials.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, gives an overview of Vulcan at the 2023 DPHARM conference in Boston, MA.

Amy Cramer, steering committee board co-chair, HL7 FHIR Accelerator Vulcan, shares what she is currently seeing in the data space of clinical trials at the 2023 DPHARM conference in Boston, MA.

How can industry bring its latest technologies together?

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses what the future of patient recruitment could look like at the 2023 DPHARM conference in Boston, MA.

Colleen Hoke, co-founder and CEO, ObjectiveHealth discusses the challenges industry is currently seeing in patient recruitment at the 2023 DPHARM conference in Boston, MA.

ObjectiveHealth presents real-world case study on enrollment solutions in DPHARM 2023 session.

With the recent boom in artificial intelligence (AI), industry is finding ways to best utilize it in advancing the development of potential therapies.

New models such as IROs are changing the way industry views the current site landscape and addressing challenges.